Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00783432 · ClinicalTrials.gov registry record · Phase 3
Study to Evaluate the Safety and Tolerability of a Nasal Spray in Patients With Chronic Allergic or Nonallergic Rhinitis
A Phase 3 study, sponsored by Meda Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 862
- Enrollment target
NCT00783432: Completed Phase 3 study, sponsored by Meda Pharmaceuticals.
NCT00783432 is a Phase 3 study that has completed, run by Meda Pharmaceuticals. The registered enrollment target is 862 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00783432, a Phase 3 study, has completed, sponsored by Meda Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 862 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if Astepro Nasal Spray (0.1% azelastine hydrochloride) is as safe as Astelin Nasal Spray (0.1% azelastine hydrochloride)
Primary Outcome
An AE can be any unfavorable and unintended sign,symptom, or disease temporally associated with the use of this investigational product, whether or not considered related to the investigational product. An AE is any untoward medical occurrence in a subject which does not necessarily have a causal relationship with this treatment.
Interventions
- DRUG Astepro Nasal Spray (0.1% azelastine hydrochloride)
- DRUG Astelin Nasal Spray (0.1% azelastine hydrochloride)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 862 participants |
| Start Date | 2006-07 |
| Est. Completion | 2007-12 |
| Phase | Phase 3 |
What the finished NCT00783432 record still lists
NCT00783432 is an interventional study that assigns participants to a tested intervention. The registered 862 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (12% higher).
The record links to 0 conditions, and to 2 interventions - of which Astepro Nasal Spray (0.1% azelastine hydrochloride) is the first listed.
NCT00783432 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00783432 about?
NCT00783432 is a clinical study titled "Study to Evaluate the Safety and Tolerability of a Nasal Spray in Patients With Chronic Allergic or Nonallergic Rhinitis". The purpose of this study is to determine if Astepro Nasal Spray (0.1% azelastine hydrochloride) is as safe as Astelin Nasal Spray (0.1% azelastine hydrochloride)
What is the current status of trial NCT00783432?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 862 participants. The study started on 2006-07. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00783432?
The interventions under investigation include: Astepro Nasal Spray (0.1% azelastine hydrochloride) (DRUG), Astelin Nasal Spray (0.1% azelastine hydrochloride) (DRUG).
Who is sponsoring clinical trial NCT00783432?
This trial is sponsored by Meda Pharmaceuticals, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00783432's enrollment target sits among peer trials
862 380th of 2000 higher than 1,621 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05914116 · 862 participants · Phase 1
A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
- NCT06256588 · 864 participants · Phase 3
A Study of Dostarlimab vs Placebo After Chemoradiation in Adult Participants With Locally Advanced Unresected Head and Neck Squamous Cell Carcinoma
- NCT06527794 · 864 participants · NA
Remote Hypertension Management for Black Patients
- NCT04541381 · 860 participants · NA
The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia